Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label Sorafenib. Show all posts
Showing posts with label Sorafenib. Show all posts
Wednesday, May 23, 2012

Dr Curiel/Viral Genetics' P-IND Clears FDA To Commence Clinical Trials (ovarian cancer/Sorafenib) in Humans - MarketWatch

›
Viral Genetics' P-IND Clears FDA To Commence Clinical Trials in Humans - MarketWatch Viral Genetics' P-IND Clears FDA To Commenc...
Wednesday, January 25, 2012

abstract: Antiangiogenic Agents in Combination With Chemotherapy for the Treatment of Epithelial Ovarian Cancer

›
Objective: The purpose of this review was to provide an overview of angiogenesis, including the rationale for targeting angiogenesis ...
Thursday, January 19, 2012

abstract: RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors (vemurafenib/sorafenib/secondary malignancies)

›
"Purpose   RAF inhibitors are effective against melanomas with BR...
Saturday, January 07, 2012

open access: Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib

›
Background: This study describes a repeated measures prediction index to identify patients at high risk of ≥ grade 2 hand-foot skin react...
Tuesday, January 03, 2012

Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1

›
Conclusion: Sorafenib induces keratinocyte proliferation in vivo and a time- and dose-dependent activation of the MAP kinase pathway in ...
Monday, March 28, 2011

Expert Review - slides: Renal Cell Carcinoma Biology and the Rationale for VEGF (sorafenib, sunitinib, erlotinib, avastin, interleukins, etc)

›
Note: if you are unable to access this slide presentation it is because you need to register on the site (free); it may be of interest to t...
Wednesday, December 29, 2010

abstract: Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial — JCO

›
Conclusion: Sorafenib has modest antitumor activity in patients with recurrent OC, but the activity was at the expense of substantial toxic...
Monday, September 20, 2010

Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium

›
Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; †Juravinski Cancer Centre, McMaster University,Hamilton, Onta...
Wednesday, September 08, 2010

abstract: Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. - in research- Cancer Science

›
Tuesday, August 24, 2010

JCO: Lettter: Risk of Arterial Thrombosis Not Increased by Sorafenib or Sunitinib

›
Note: analyzing the research including a reference to Avastin
Saturday, July 17, 2010

Abstract/full acess: Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

›
Background: Hypertension (HT) and hand-foot skin reactions (HFSR) may be related to the activity of bevacizumab and sorafenib. We hypothesi...
Thursday, June 17, 2010

Cardiovascular Safety of VEGF-Targeting Therapies: Current Evidence and Handling Strategies -- Girardi et al., 10.1634/theoncologist.2009-0235 -- The Oncologist

›
Abstract Treatment with the angiogenesis inhibitors bevacizumab, sunitinib, and sorafenib as single agents or in combination with convent...
Wednesday, April 14, 2010

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer

›
Note: this would have been a phase 1 trial Results Four patients were enrolled. After preoperative treatment and cytoreductive surgery, al...
Saturday, March 13, 2010

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.

›
RESULTS: .....Four patients were enrolled. After preoperative treatment and cytoreductive surgery, all patients were excluded from protoco...
Sunday, March 07, 2010

repost: Combination therapy: intermittent Sorafenib with (Avastin) bevacizumab yields activity and decreased toxicity.

›
Tuesday, February 23, 2010

Toxicity of sorafenib: clinical and molecular aspects; Expert Opinion on Drug Safety - abstract

›
Take home message: Although not life-threatening, toxicity of sorafenib can severely impact the physical, psychological and social well-bei...
Friday, January 22, 2010

abstract: Association of Skeletal Muscle Wasting With Treatment With Sorafenib

›
Note: this study is not specific to ovarian cancer but may be of interest for those deciding on Sorafenib:
Tuesday, January 19, 2010

abstract: Safety and efficacy results of the advanced renal cell carcinoma Sorafenib expanded access program in North America

›
Note : while this is not specific to ovarian cancer knowing the side effects which patients experienced may be helpful